70 / 100

Dr. Junfang Zheng | Molecular Biology Award | Best Researcher Award

Dr. Junfang Zheng, Capital medical university, China

Based on Dr. Junfang Zhengā€™s academic background, current and previous appointments, and honors and awards, he appears to be a strong candidate for the Research for Best Researcher Award. Hereā€™s an evaluation of his qualifications:

Publication profile

Scopus

Education:

Dr. Zheng has a solid educational foundation with a B.M. in Traditional Chinese Medicine from Shanxi University of Chinese Medicine, followed by an M.Sc. in Diagnostics of Traditional Chinese Medicine from Beijing University of Chinese Medicine. His Ph.D. in Pathogenic Biology from Peking University further strengthens his expertise, indicating a robust background in both traditional and modern aspects of medical research.

Current Appointment:

Since 2006, Dr. Zheng has been a Professor in the Department of Biochemistry and Molecular Biology at Capital Medical University. This long-term position reflects his established career and significant contributions to his field.

Previous Appointments:

Dr. Zhengā€™s previous roles include a Visiting Fellow at the Medical University of Vienna and a Postdoctoral Fellow at Tsinghua University. These positions highlight his international experience and commitment to advancing his research in different academic environments.

Honors, Awards, and Grants:

Dr. Zheng has received multiple prestigious awards, including the Guanghua Fellowship from Peking University, the Eurasia Pacific Uninet Scholarship from Austria, and several funds and honors from Beijing and China. These recognitions underscore his high-impact research contributions and the esteem in which he is held within the academic community.

Publication Top Notes Ā 

  • YTHDF3 phase separation regulates HSPA13-dependent clear cell renal cell carcinoma development and immune evasion šŸ§¬ ā€” Cancer Science, 2024, 0 citations
  • PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway šŸ§Ŗ ā€” Cell Death and Disease, 2024, 0 citations
  • ARHGAP11A Is a Novel Prognostic and Predictive Biomarker Correlated with Immunosuppressive Microenvironment in Clear Cell Renal Cell Carcinoma šŸ”¬ ā€” International Journal of Molecular Sciences, 2023, 2 citations
  • GLUD1 suppresses renal tumorigenesis and development via inhibiting PI3K/Akt/mTOR pathway šŸ§« ā€” Frontiers in Oncology, 2022, 6 citations
  • Inhibitor tolerance and bioethanol fermentability of levoglucosan-utilizing Escherichia coli were enhanced by overexpression of stress-responsive gene ycfR šŸ”¬ ā€” Synthetic and Systems Biotechnology, 2021, 4 citations
  • Bioactive peptide apelin rescues acute kidney injury by protecting the function of renal tubular mitochondria šŸ§¬ ā€” Amino Acids, 2021, 11 citations
  • SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis šŸ§Ŗ ā€” Frontiers in Oncology, 2021, 28 citations
  • iTRAQ-facilitated proteomic analysis of Bacillus cereus via degradation of malachite green šŸ”¬ ā€” Journal of Microbiology, 2021, 2 citations
  • Long noncoding RNA PENG upregulates PDZK1 expression by sponging miR-15b to suppress clear cell renal cell carcinoma cell proliferation šŸ§¬ ā€” Oncogene, 2020, 26 citations
  • ECHS1 suppresses renal cell carcinoma development through inhibiting mTOR signaling activation šŸ”¬ ā€” Biomedicine and Pharmacotherapy, 2020, 16 citations


Conclusion

Dr. Zhengā€™s extensive educational background, notable appointments, and numerous awards make him a highly suitable candidate for the Research for Best Researcher Award. His achievements and international experience align well with the criteria for such an award.

Junfang Zheng | Molecular Biology Award | Best Researcher Award

You May Also Like